|
Bruce serves as Chairman of the Board for Metastatix. He is also a Managing Director at H.I.G. Ventures. Bruce is also on the board of CardioFocus and recently served on the boards of IntraPace, Pepgen, and CGI Pharma (observer).Bruce has been active in the life sciences sector for 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.Bruce is on the boards of the Mid-Atlantic Venture Association, the Georgia Biomedical Partnership, Shady Grove Hospital, the BioLife Fund of Virginia’s Center for Innovative Technology, and the University of Delaware Research Foundation. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School. | 